Expert Discusses Promise of Quizartinib in AML
Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.
Pan-Kinase Inhibition Key to Midostaurin Benefit in AML
FLT3 targeted agents are emerging in the treatment of acute myeloid leukemia, and which specific agent will be most effective is highly dependent on whether a patient has been previously treated.
Immunotherapy Makes Comeback in RCC, But Challenges Remain
Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.
Immunotherapy Combos on Horizon in First-Line RCC
Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.
Tumor-Treating Fields Make Significant Impact in GBM
It’s not often that oncologists get to be the first to utilize cutting-edge technology.
Third-Generation TKI Most Promising Option for Ph+ ALL
Tyrosine-kinase inhibitors have considerably improved survival outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lead PALOMA-2 Author Says Results Will Boost Global Use of Palbociclib
Results from the phase III PALOMA-2 study—which demonstrated a significant progression-free survival advantage with palbociclib (Ibrance) plus letrozole compared with letrozole alone in ER-positive, HER2-negative metastatic breast cancer—were recently published in The New England Journal of Medicine.
Investigating EGFR Resistance Leads to New Therapies, Advances in NSCLC
While resistance to EGFR-targeted therapies in non–small cell lung cancer presents a major challenge, there is a silver lining.
I-SPY 2 Paves the Way for Novel HER2-Targeted Agents in Breast Cancer
There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.
Cetuximab Benefit, Tumor Sidedness Impact Still Unclear in mCRC
Alan P. Venook, MD, discusses key issues in metastatic colorectal cancer, including tumor sidedness and the conflicting data regarding the precise benefit of cetuximab in the frontline setting.
Expert Explains Sequencing Considerations for Regorafenib and TAS-102 in mCRC
For a long time, patients with metastatic colorectal cancer had poor outcomes and very limited treatment options, said Tanios Bekaii-Saab, MD.
New Options Emerge in Frontline, Adjuvant RCC Care
Therapeutic options for patients with renal cell carcinoma have increased rapidly in the past decade, yet the field is still poised to expand significantly in the coming years, said Robert S. Alter, MD.
HPV-Vaccinated Patients Require Less Frequent Cervical Cancer Screening
Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.
Newly Identified Molecular Subtypes Could Guide Treatment Decisions in Prostate Cancer
Researchers have identified 3 distinct molecular subtypes of primary prostate cancer that correlate with distant metastasis-free survival and response to radiation therapy.
Regorafenib Renews Hope in Hepatocellular Carcinoma
There has been renewed optimism in hepatocellular carcinoma with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA.
Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients
Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.
Nilotinib/Trametinib Show Early Promise in BRAF/NRAS Wild-Type Melanoma
The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma.
More Than Half of Cervical Cancer Patients Not Receiving Recommended Treatment
Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.
Immunotherapy, MEK Inhibitor Combo Effective for BRAF Wild-Type Melanoma
The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.
Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment
Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.